Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Autor: Serge Jabbour, Natalie Halladin, Keval Chandarana, Stewart B. Harris, Rudolf Prager, Győző Kocsis, Terry Ridge
Rok vydání: 2016
Předmět:
Insulin degludec
Blood Glucose
Male
randomized clinical trials
Endocrinology
Diabetes and Metabolism
efficacy
Once weekly
Type 2 diabetes
030204 cardiovascular system & hematology
Gastroenterology
law.invention
0302 clinical medicine
Endocrinology
Randomized controlled trial
law
Medicine
Middle Aged
Metformin
Insulin
Long-Acting
Drug Combinations
Treatment Outcome
Drug Therapy
Combination
Female
Original Article
type 2 diabetes
Algorithms
medicine.drug
safety
medicine.medical_specialty
030209 endocrinology & metabolism
Equivalence Trials as Topic
Drug Administration Schedule
03 medical and health sciences
Internal medicine
Internal Medicine
Humans
Hypoglycemic Agents
In patient
Adverse effect
Aged
Glycated Hemoglobin
Pioglitazone
business.industry
Liraglutide
Weight change
Original Articles
medicine.disease
Surgery
Diabetes Mellitus
Type 2
insulin therapy
Thiazolidinediones
business
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1463-1326
Popis: Aims To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide (IDegLira) with that used in previous DUAL trials in insulin-naive patients with type 2 diabetes. Research design and methods This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-breakfast PG readings (n = 210). Results Mean HbA1c decreased from 8.2% (65 mmol/mol) to 6.1% (43 mmol/mol) with once-weekly titration and from 8.1% (65 mmol/mol) to 6.0% (42 mmol/mol) with twice-weekly titration; non-inferiority was confirmed (estimated treatment difference: 0.12% [−0.04; 0.28]95% CI , 1.30 mmol/mol [−0.41; 3.01]95% CI ). Approximately 90% of patients achieved HbA1c
Databáze: OpenAIRE
Externí odkaz: